Human Immunodeficiency Virus (HIV), Arterial Dysfunction, Lipids, Lovaza (HALO) Trial
| Status: | Archived |
|---|---|
| Conditions: | Peripheral Vascular Disease, HIV / AIDS |
| Therapuetic Areas: | Cardiology / Vascular Diseases, Immunology / Infectious Diseases |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 7/1/2011 |
| Start Date: | July 2008 |
| End Date: | January 2010 |
The purpose of this study is to determine whether fish oil supplementation with Lovaza,
formally known as Omacor will result in a significant reduction in serum triglyceride (TG),
an increase in high density lipoprotiens (HDL), and an improvement of endothelial
dysfunction.
This is a randomized, double blind, placebo controlled, cross-over, clinical trial to
determine the effect of fish oil supplementation with Lovaza® on triglyceride levels in
HIV-infected subjects on HAART with elevated serum triglycerides. The sample size is 40
subjects. The total duration of the study is 28 weeks, with 12-week treatment periods
separated by a 4-week washout. This study will be conducted at the Clinical Research Center
at Tufts Medical Center.
We found this trial at
1
site
Click here to add this to my saved trials
